Glycans in melanoma: Drivers of tumour progression but sweet targets to exploit for immunotherapy

IF 4.9 3区 医学 Q2 IMMUNOLOGY
Immunology Pub Date : 2024-05-14 DOI:10.1111/imm.13801
Camille Niveau, Eleonora Sosa Cuevas, Philippe Saas, Caroline Aspord
{"title":"Glycans in melanoma: Drivers of tumour progression but sweet targets to exploit for immunotherapy","authors":"Camille Niveau,&nbsp;Eleonora Sosa Cuevas,&nbsp;Philippe Saas,&nbsp;Caroline Aspord","doi":"10.1111/imm.13801","DOIUrl":null,"url":null,"abstract":"<p>Aberrant glycosylation recently emerged as an unmissable hallmark of cancer progression in many cancers. In melanoma, there is growing evidence that the tumour ‘glycocode’ plays a major role in promoting cell proliferation, invasion, migration, but also dictates the nature of the immune infiltrate, which strongly affects immune cell function, and clinical outcome. Aberrant glycosylation patterns dismantle anti-tumour defence through interactions with lectins on immune cells, which are crucial to shape anti-tumour immunity but also to trigger immune evasion. The glycan/lectin axis represents a new immune subversion pathway that is exploited by melanoma to hijack immune cells and escape from immune control. In this review, we describe the glycosylation features of melanoma tumour cells, and further gather findings related to the role of glycosylation in melanoma tumour progression, deciphering in detail its impact on immunity. We also depict glycan-based strategies aiming at restoring a functional anti-tumour response in melanoma patients. Glycans/lectins emerge as key immune checkpoints with promising translational properties. Exploitation of these pathways could reshape potent anti-tumour immunity while impeding immunosuppressive circuits triggered by aberrant tumour glycosylation patterns, holding great promise for cancer therapy.</p>","PeriodicalId":13508,"journal":{"name":"Immunology","volume":null,"pages":null},"PeriodicalIF":4.9000,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imm.13801","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/imm.13801","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aberrant glycosylation recently emerged as an unmissable hallmark of cancer progression in many cancers. In melanoma, there is growing evidence that the tumour ‘glycocode’ plays a major role in promoting cell proliferation, invasion, migration, but also dictates the nature of the immune infiltrate, which strongly affects immune cell function, and clinical outcome. Aberrant glycosylation patterns dismantle anti-tumour defence through interactions with lectins on immune cells, which are crucial to shape anti-tumour immunity but also to trigger immune evasion. The glycan/lectin axis represents a new immune subversion pathway that is exploited by melanoma to hijack immune cells and escape from immune control. In this review, we describe the glycosylation features of melanoma tumour cells, and further gather findings related to the role of glycosylation in melanoma tumour progression, deciphering in detail its impact on immunity. We also depict glycan-based strategies aiming at restoring a functional anti-tumour response in melanoma patients. Glycans/lectins emerge as key immune checkpoints with promising translational properties. Exploitation of these pathways could reshape potent anti-tumour immunity while impeding immunosuppressive circuits triggered by aberrant tumour glycosylation patterns, holding great promise for cancer therapy.

Abstract Image

黑色素瘤中的糖类:肿瘤进展的驱动因素,但也是免疫疗法可利用的甜蜜目标。
最近,糖基化异常已成为许多癌症进展过程中不可忽视的标志。在黑色素瘤中,越来越多的证据表明,肿瘤的 "糖代码 "在促进细胞增殖、侵袭和迁移方面起着重要作用,而且还决定着免疫浸润的性质,这对免疫细胞的功能和临床结果都有很大影响。异常的糖基化模式通过与免疫细胞上的凝集素相互作用而破坏抗肿瘤防御,这对形成抗肿瘤免疫至关重要,但也会引发免疫逃避。糖基化/凝集素轴代表了一种新的免疫颠覆途径,黑色素瘤利用这种途径劫持免疫细胞,逃避免疫控制。在这篇综述中,我们描述了黑色素瘤肿瘤细胞的糖基化特征,并进一步收集了与糖基化在黑色素瘤肿瘤进展中的作用有关的研究结果,详细解读了糖基化对免疫的影响。我们还描绘了以糖基化为基础的策略,旨在恢复黑色素瘤患者的功能性抗肿瘤反应。聚糖/集电极蛋白是关键的免疫检查点,具有广阔的转化前景。利用这些途径可以重塑有效的抗肿瘤免疫,同时阻碍由异常肿瘤糖基化模式引发的免疫抑制回路,为癌症治疗带来巨大希望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Immunology
Immunology 医学-免疫学
CiteScore
11.90
自引率
1.60%
发文量
175
审稿时长
4-8 weeks
期刊介绍: Immunology is one of the longest-established immunology journals and is recognised as one of the leading journals in its field. We have global representation in authors, editors and reviewers. Immunology publishes papers describing original findings in all areas of cellular and molecular immunology. High-quality original articles describing mechanistic insights into fundamental aspects of the immune system are welcome. Topics of interest to the journal include: immune cell development, cancer immunology, systems immunology/omics and informatics, inflammation, immunometabolism, immunology of infection, microbiota and immunity, mucosal immunology, and neuroimmunology. The journal also publishes commissioned review articles on subjects of topical interest to immunologists, and commissions in-depth review series: themed sets of review articles which take a 360° view of select topics at the heart of immunological research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信